Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline

Bridge Medicines Signs Agreement with The Rockefeller University for Further Preclinical Development of Breslow Lab Assets

NEW YORK, NEW YORK – September 21, 2020

Bridge Medicines and The Rockefeller University today announced an exclusive license agreement to further develop a series of small molecule inhibitors of activated Factor XII (FXIIa) discovered in the laboratory of Jan L. Breslow, M.D.